Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Quadramet (Samarium) Promising New Treatment Option For Osteosarcoma PRINCETON, NJ -- February 21, 2002 -- A new study shows that Quadramet® (samarium), developed by Cytogen and approved by the U.S. Food and Drug administration in 1997 for the treatment of pain in patients with metastatic bone lesions, can be used at higher doses to treat osteosarcoma, the most common type of cancer that develops in bone. The results of the study were recently published in the Journal of Clinical Oncology (2002,20:189-196). According to the study conducted by researchers at the Mayo Clinic, 24 out of 30 patients undergoing treatment with Quadramet experienced good to excellent results in delaying local progression of the cancer. All of the patients in the study had failed two or more previous therapies and had multiple sites of bone cancer. In two patients, the cancer has been in complete remission for more than two years following treatment. "Quadramet is an effective treatment option in helping to relieve the pain often experienced by patients with metastatic bone cancer. We are very encouraged by these early results that indicate Quadramet may also be useful in the treatment of osteosarcoma," said H. Joseph Reiser, Ph.D., president and CEO of Cytogen Corporation. Osteosarcoma is the most common type of cancer that develops in bone. It occurs most often in teenagers and is twice as common in males as it is in females. Surgery and chemotherapy are the two most common forms of treatment for osteosarcoma. "In some patients, surgery or chemotherapy cannot adequately control osteosarcoma. These study results indicate that samarium (Quadramet) could be a new treatment option for patients who would otherwise have a poor prognosis, "said Peter Anderson, M.D., Ph.D., a pediatric oncologist at Mayo Clinic. Quadramet consists of a radioactive isotope, Samarium 153, which emits beta radiation, and a chelating agent, EDTMP, which targets the drug to sites of new bone formation. Primary bone cancers commonly result in the formation of new bone regardless of whether the tumor remains confined to the skeleton or has spread to soft tissues such as the lung. By targeting these areas of new bone formation, Quadramet delivers site-specific radiation to these cancers. Quadramet is marketed by Berlex Laboratories, the U.S. affiliate of Schering AG Germany, in the United States. SOURCE Cytogen Corporation E-mail this page to a friend or colleague! To print, use this version